GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 895 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 895 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $33.33, for a total value of $29,830.35. Following the transaction, the chief financial officer now directly owns 39,910 shares of the company’s stock, valued at approximately $1,330,200.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The stock was sold at an average price of $31.71, for a total value of $8,308.02.
• On Monday, July 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $33.54, for a total value of $9,189.96.
• On Monday, June 17th, Kevin Feeley sold 2,646 shares of GeneDx stock. The shares were sold at an average price of $28.31, for a total transaction of $74,908.26.

GeneDx Stock Up 4.7 %

Shares of NASDAQ:WGS opened at $35.26 on Thursday. The company has a 50 day moving average price of $32.49 and a two-hundred day moving average price of $22.21. The company has a market capitalization of $921.06 million, a PE ratio of -6.81 and a beta of 2.29. GeneDx Holdings Corp. has a 52 week low of $1.16 and a 52 week high of $37.45. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.22 and a current ratio of 2.38.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.15. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. Analysts forecast that GeneDx Holdings Corp. will post -0.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new position in GeneDx in the second quarter valued at approximately $34,000. nVerses Capital LLC acquired a new position in shares of GeneDx during the 2nd quarter worth about $50,000. Thompson Davis & CO. Inc. grew its holdings in GeneDx by 20.8% during the first quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock worth $220,000 after purchasing an additional 4,150 shares during the period. Decheng Capital LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $285,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of GeneDx during the 2nd quarter worth approximately $290,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on WGS shares. BTIG Research raised their price objective on GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Company initiated coverage on shares of GeneDx in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $34.00 price objective on the stock. TD Cowen raised their price objective on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Craig Hallum increased their price target on GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, The Goldman Sachs Group lifted their price objective on GeneDx from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.